Retrophin, Inc. OTCQB: RTRX New York based, biotechnology company focused on discovering and developing treatments for rare and life threatening diseases. Retrophin is currently developing treatments for Focal Segmental Glomerulosclerosis FSGS , Pantothenate Kinase Associated Neurodegeneration PKAN , Duchenne Muscular Dystrophy DMD , and Spinal Muscular Atrophy SMA .
Quote | Travere Therapeutics (NASDAQ:RTRX)
Last: | $24.24 |
---|---|
Change Percent: | -0.49% |
Open: | $24.57 |
Close: | $24.24 |
High: | $24.74 |
Low: | $24.04 |
Volume: | 378,991 |
Last Trade Date Time: | 11/18/2020 04:56:39 pm |
News | Travere Therapeutics (NASDAQ:RTRX)
Travere Therapeutics (TVTX) has completed enrollment in the Phase 3 DUPLEX study evaluating sparsentan for the treatment of focal segmental glomerulosclerosis ((FSGS)), a rare kidney condition that often leads to end-stage kidney disease ((ESKD)). Topline efficacy data is expected in Q1 of 20...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
Message Board Posts | Travere Therapeutics (NASDAQ:RTRX)
Subject | By | Source | When |
---|---|---|---|
Got snuffed for half when it dipped to | KOmani | investorshub | 08/22/2019 7:43:00 PM |
Glad I never jumped in. | Glider549 | investorshub | 08/22/2019 3:40:38 PM |
As of last public report, more than 4 | KOmani | investorshub | 08/22/2019 2:26:34 PM |
Seems like a good chunk of the selling | KOmani | investorshub | 08/22/2019 2:20:59 PM |
Seems markets didnt like phase 3 results | stock1ace1 | investorshub | 08/22/2019 11:57:52 AM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Travere Therapeutics (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 DUPLEX Study. The pivotal DUPLEX Study is evaluating the safety and efficacy of sparsentan for the treatment of focal segmental glomerulosclerosis...
New name reflects dedication to patient- inspired mission of identifying, developing and delivering life-changing rare disease therapies Company’s s hares to t rade u nder n ew t icker s ymbol TVTX on Novem...
SAN DIEGO, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the completion of its previously announced acquisition of Orphan Technologies Limited, a privately held, clinical-stage biopharmaceutical company focused on the development of product candidate OT-58...